FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2942598113> ?p ?o ?g. }

• W2942598113 endingPage "117956031984645" @default.
• W2942598113 startingPage "117956031984645" @default.
• W2942598113 abstract "Studies have shown an association between continuous renal replacement therapy (CRRT) and thrombocytopenia. Patients on CRRT usually receive unfractionated heparin (UFH), and heparin-induced thrombocytopenia (HIT) is frequently suspected as a potential cause of thrombocytopenia. In the setting of HIT suspicion, changes in anticoagulation may put patients at risk of developing thromboembolic events or adverse medication effects. Purpose: The purpose of this study was to investigate current management of anticoagulation in patients with suspected HIT while on CRRT and identify complications associated with anticoagulation in this setting. Methods: This is a retrospective study of patients on CRRT with suspicion for HIT. Prevalence of HIT and anticoagulant use were collected for all patients. Outcomes included thromboembolic and bleeding events, final therapeutic doses of each anticoagulant, and time to reach therapeutic range. Thromboembolic and bleeding outcomes were compared between anticoagulants. Results: From January 2013 through December 2015, 74 patients were identified with suspicion of HIT while on CRRT. During the period of HIT suspicion, 20 patients received argatroban, 18 received bivalirudin, 1 received fondaparinux, 4 received UFH infusions, 10 received prophylactic dosing subcutaneous UFH, and 21 received no anticoagulation. The median final therapeutic doses of argatroban and bivalirudin were 1.00 μg/kg/min and 0.075 mg/kg/h, respectively, with no difference in time to therapeutic range (17.6 h vs 18.2 h, P = .485). Compared with bivalirudin, patients treated with argatroban had significantly more therapeutic activated partial thromboplastin time (aPTT) values (54.5% vs 42.8%, P = .008). Four patients (20.0%) treated with argatroban and 5 patients (27.8%) treated with bivalirudin experienced major bleeding ( P = .709). Three patients (15.0%) treated with argatroban and 4 patients (22.2%) treated with bivalirudin experienced thromboembolic events ( P = .687). Conclusion: Argatroban and bivalirudin were associated with similar rates of bleeding and thromboembolic events during the period of concurrent CRRT and thrombocytopenia, although patients treated with argatroban had more therapeutic aPTT values." @default.
• W2942598113 created "2019-05-09" @default.
• W2942598113 creator A5006470424 @default.
• W2942598113 creator A5012481255 @default.
• W2942598113 creator A5014192307 @default.
• W2942598113 creator A5025017115 @default.
• W2942598113 date "2019-01-01" @default.
• W2942598113 modified "2023-09-23" @default.
• W2942598113 title "Evaluation of the Use of Argatroban or Bivalirudin for the Management of Suspected Heparin-Induced Thrombocytopenia in the Setting of Continuous Renal Replacement Therapy" @default.
• W2942598113 cites W1837061770 @default.
• W2942598113 cites W1965864660 @default.
• W2942598113 cites W1969719994 @default.
• W2942598113 cites W1978093544 @default.
• W2942598113 cites W1982536750 @default.
• W2942598113 cites W1984138867 @default.
• W2942598113 cites W1990134290 @default.
• W2942598113 cites W1994587232 @default.
• W2942598113 cites W2018203403 @default.
• W2942598113 cites W2030143427 @default.
• W2942598113 cites W2045865674 @default.
• W2942598113 cites W2048499539 @default.
• W2942598113 cites W2049055287 @default.
• W2942598113 cites W2107304934 @default.
• W2942598113 cites W2111830391 @default.
• W2942598113 cites W2112422091 @default.
• W2942598113 cites W2125202550 @default.
• W2942598113 cites W2133880580 @default.
• W2942598113 cites W2140436541 @default.
• W2942598113 cites W2150922204 @default.
• W2942598113 cites W2153622822 @default.
• W2942598113 cites W2155167030 @default.
• W2942598113 cites W2162340010 @default.
• W2942598113 cites W2210102018 @default.
• W2942598113 cites W2518420743 @default.
• W2942598113 cites W2989714602 @default.
• W2942598113 cites W4234489211 @default.
• W2942598113 cites W567915334 @default.
• W2942598113 doi "https://doi.org/10.1177/1179560319846452" @default.
• W2942598113 hasPublicationYear "2019" @default.
• W2942598113 type Work @default.
• W2942598113 sameAs 2942598113 @default.
• W2942598113 citedByCount "2" @default.
• W2942598113 countsByYear W29425981132020 @default.
• W2942598113 countsByYear W29425981132022 @default.
• W2942598113 crossrefType "journal-article" @default.
• W2942598113 hasAuthorship W2942598113A5006470424 @default.
• W2942598113 hasAuthorship W2942598113A5012481255 @default.
• W2942598113 hasAuthorship W2942598113A5014192307 @default.
• W2942598113 hasAuthorship W2942598113A5025017115 @default.
• W2942598113 hasBestOaLocation W29425981131 @default.
• W2942598113 hasConcept C126322002 @default.
• W2942598113 hasConcept C141071460 @default.
• W2942598113 hasConcept C167135981 @default.
• W2942598113 hasConcept C2776301958 @default.
• W2942598113 hasConcept C2776472838 @default.
• W2942598113 hasConcept C2776710957 @default.
• W2942598113 hasConcept C2776877702 @default.
• W2942598113 hasConcept C2777288759 @default.
• W2942598113 hasConcept C2777292125 @default.
• W2942598113 hasConcept C2777557582 @default.
• W2942598113 hasConcept C2777565915 @default.
• W2942598113 hasConcept C2778205648 @default.
• W2942598113 hasConcept C2778261982 @default.
• W2942598113 hasConcept C2778810321 @default.
• W2942598113 hasConcept C2779161974 @default.
• W2942598113 hasConcept C2779541074 @default.
• W2942598113 hasConcept C2779612170 @default.
• W2942598113 hasConcept C2780400711 @default.
• W2942598113 hasConcept C2780868729 @default.
• W2942598113 hasConcept C2991741193 @default.
• W2942598113 hasConcept C42219234 @default.
• W2942598113 hasConcept C500558357 @default.
• W2942598113 hasConcept C71924100 @default.
• W2942598113 hasConcept C89560881 @default.
• W2942598113 hasConceptScore W2942598113C126322002 @default.
• W2942598113 hasConceptScore W2942598113C141071460 @default.
• W2942598113 hasConceptScore W2942598113C167135981 @default.
• W2942598113 hasConceptScore W2942598113C2776301958 @default.
• W2942598113 hasConceptScore W2942598113C2776472838 @default.
• W2942598113 hasConceptScore W2942598113C2776710957 @default.
• W2942598113 hasConceptScore W2942598113C2776877702 @default.
• W2942598113 hasConceptScore W2942598113C2777288759 @default.
• W2942598113 hasConceptScore W2942598113C2777292125 @default.
• W2942598113 hasConceptScore W2942598113C2777557582 @default.
• W2942598113 hasConceptScore W2942598113C2777565915 @default.
• W2942598113 hasConceptScore W2942598113C2778205648 @default.
• W2942598113 hasConceptScore W2942598113C2778261982 @default.
• W2942598113 hasConceptScore W2942598113C2778810321 @default.
• W2942598113 hasConceptScore W2942598113C2779161974 @default.
• W2942598113 hasConceptScore W2942598113C2779541074 @default.
• W2942598113 hasConceptScore W2942598113C2779612170 @default.
• W2942598113 hasConceptScore W2942598113C2780400711 @default.
• W2942598113 hasConceptScore W2942598113C2780868729 @default.
• W2942598113 hasConceptScore W2942598113C2991741193 @default.
• W2942598113 hasConceptScore W2942598113C42219234 @default.
• W2942598113 hasConceptScore W2942598113C500558357 @default.
• W2942598113 hasConceptScore W2942598113C71924100 @default.
• W2942598113 hasConceptScore W2942598113C89560881 @default.

• next